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Abstract
Background: A Finnish joint research effort Kuopio Birth Cohort (KuBiCo) seeks to evaluate the effects of genetics,
epigenetics and different risk factors (medication, nutrition, lifestyle factors and environmental aspects) during
pregnancy on the somatic and psychological health status of the mother and the child.
Methods: KuBiCo will ultimately include information on 10,000 mother-child pairs who have given their informed
consent to participate in this cohort. Identification of foetal health risk factors that can potentially later manifest as
disease requires a repository of relevant biological samples and a flexible open up-to-date data handling system to
register, store and analyse biological, clinical and questionnaire-based data. KuBiCo includes coded questionnaire-
based maternal background data gathered before, during and after the pregnancy and bio-banking of maternal
and foetal samples that will be stored in deep freezers. Data from the questionnaires and biological samples will be
collected into one electronic database. KuBiCo consists of several work packages which are complementary to each
other: Maternal, foetal and placental metabolism and omics; Paediatrics; Mental wellbeing; Prenatal period and delivery;
Analgesics and anaesthetics during peripartum period; Environmental effects; Nutrition; and Research ethics.
Discussion: This report describes the set-up of the KuBiCo and descriptive analysis from 3532 parturients on response
frequencies and feedback to KuBiCo questionnaires gathered from June 2012 to April 2016. Additionally, we describe
basic demographic data of the participants (n = 1172). Based on the comparison of demographic data between official
national statistics and our descriptive analysis, KuBiCo represents a cross-section of Finnish pregnant women.
Keywords: Birth weight, Environmental health, Foetus, Maternal smoking, Mental health, Metabolism, Nutrition,
Paediatrics, Placenta, Research ethics
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Background
Population-based pregnancy cohorts have demonstrated
that foetal growth, exposure to smoking and pollutants
as well as the presence of maternal diseases, the domes-
tic environment, psychological stress and nutrition have
long-term effects on the health of the offspring [1, 2].
One way to investigate the multiple associations between
the effects of prenatal exposure and health of the
offspring later in life is via birth cohorts that combine
clinical, questionnaire and biological data in a way that
is easy to link. According to the Declaration of Helsinki
(www.wma.net) and legislation in many countries in-
cluding Finland (488/1999; www.finlex.fi), research eth-
ics in human studies requires special attention. However,
how to carry out practical procedures in cohort studies
in ethically best way is not self-evident and requires
further studies [3].
Human foetus is much more sensitive than adult to
the adverse effects of chemicals or other risk factors.
This is due to the on-going development, characterized
by high cell proliferation capacity combined with defi-
ciencies in the foetal metabolic detoxification capacity,
an immature immune system and still-developing
DNA-repair mechanisms [4]. At this stage, chemicals
can permanently reprogram physiological responses
through epigenetic mechanisms increasing the suscepti-
bility of the foetus to diseases appearing after birth [5].
These modifications can be analysed, for instance, by
RNA sequencing, metabolomics, proteomics and epigen-
etics [6–8]. In addition, it has also been demonstrated
that maternal health status during pregnancy predicts
future wellbeing of the child and mother [9].
Alterations occurring during the pre-, peri- and post-
natal developmental periods can increase sensitivity for
further aberrations at later stages of life [10]. Human
data supporting this hypothesis emerges from studies
showing that aberrant programming of growth and devel-
opment can lead to respiratory disease [11], non-Hodgkin
lymphoma [12] and neurological diseases [13].
In Finland, approximately 50% of pregnant women
consume medicinal products during their pregnancy
[14]. In addition to medicinal products, natural and
herbal medications are frequently used during preg-
nancy, and should be considered as a possible foetal risk
factor [15]. Furthermore, up to 15% of pregnant women
smoke in Finland [16]. There is a paucity of data con-
cerning various maternal exposures during pregnancy
and their impact on overall developmental outcomes.
Nutrients and their metabolism play a crucial role in the
health and wellbeing of both mother and foetus, and they
are associated with the long-term health of the offspring
[17]. Less information exists about the intake of
non-essential nutrients and other food-based compounds
and about their association with the health of children.
Kuopio Birth Cohort (KuBiCo, www.kubico.fi) is
anchored on the concept of developmental origin of
diseases [18–20]. It will generate new knowledge by
integrating clinical and analytical data, achieving a
systematic increase in understanding the combined ef-
fects of multiple factors on health and disease. KuBiCo
is intended to help resolve the effects of genetic and
epigenetic backgrounds and potential risk factors
(medications and nutritional, lifestyle, and environmen-
tal factors) during pregnancy on the health status of the
mother and child. KuBiCo is a joint research effort
between the University of Eastern Finland (UEF), the
Kuopio University Hospital (KUH) and the National
Institute for Health and Welfare (THL).
This paper describes the setup of KuBiCo and descrip-
tive analysis of response frequencies and feedback to
KuBiCo questionnaires of altogether 3532 parturients
from June 2012 to April 2016. Additionally, we report
basic demographic data of 1172 KuBiCo participants
and show that they agree with Finnish national statistics.
Methods/design
Altogether, the final database is planned to include
10,000 mother-child pairs. All pregnant women who are
expected to give birth in KUH in the Finnish county
Northern Savo are invited to participate in KuBiCo.
KuBiCo does not include individual exclusion criteria.
Those who sign the informed consent at any stage of
pregnancy will be included in KuBiCo and prospective
data collection. Majority of the participants (> 90%) are
recruited during the routine first trimester visit (gesta-
tional week 6–9) at the prenatal clinics by primary
health care personnel or midwifes, when the pregnancy
has been determined by clinical inspection.
Collection and organization of data and samples
Barcode identification stickers with a KuBiCo code are
used to process samples into the system and archive all
biological samples (maternal and umbilical cord blood,
placental samples, microbial swab from neonate’s oral
cavity, hair and house dust samples) (Fig. 1). The groups
participating in KuBiCo will utilize the WebKuBiCo
database that sends, receives and stores all the question-
naire data from the beginning of the confirmed preg-
nancy until the child reaches adulthood. Each woman is
entered into the WebKuBiCo database by using her
personal bank account safety codes (the most widely
used electronic identification system in Finland) and
each pregnancy will have a KuBiCo code of its own.
Therefore, during the project, one woman may have sev-
eral KuBiCo codes in relation to subsequent pregnancies.
This web-based platform will also automatically create
educative/guiding feedback to the women based on their
answers to the questionnaires. So far, the service has
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been developed for mental health and nutrition ques-
tionnaires. An outline of the KuBiCo is presented in
Fig. 2.
Biological samples (maternal and umbilical cord blood,
placental tissue sample, microbial swab from neonate’s
oral cavity, maternal and foetal hair samples) are
collected by staff in KUH and the main management of
samples is conducted by personnel of UEF. House dust
samples are collected by the participating families
according to THL instructions. Biological samples are
stored in deep-freezers (− 80 °C) of KUH, UEF, and
THL. House dust samples are stored and managed in
the THL facilities.
All raw data from the questionnaires and biological
samples will be collected and stored in an electronic
KuBiCo database (eKuTKa) from which data can be
downloaded for investigation by all research partners
and international collaborators after mutual agreements.
The KuBiCo advisory board grants permissions of
KuBiCo data usage for research groups. This database
will be developed and maintained by ISTEKKI (Informa-
tion Technology services of KUH). The Bioinformatics
unit at the UEF provides the appropriate bioinformatics
software licenses, such as Revolution R Enterprise and
Ingenuity Pathway Analysis (IPA). All raw data obtained
from our own or any collaborative studies will be stored
on the eKuTKa database and analysed by the core
facilities. This will ensure continuous support for high
quality research.
Data collected in the work packages is stored in
centralized data servers. These consist of raw data,
pre-processed data, and selected results from data ana-
lysis. Central storage and processing enables efficient
curation, harmonization and integration of the data,
resulting in high quality databank that can be reliably
used for a wide range of research purposes. The data is
version controlled and backed up, ensuring efficient
storage and re-use. Access to specific parts of the data
will be controlled, allowing for functional and secure
data sharing and dissemination between the research
partners and the research community as a whole.
Standard formats for handling data from different
high-throughput technologies will be used, and such
data will be submitted to open access databases, such as
Gene Expression Omnibus (GEO), as required by scien-
tific journals upon publication.
To ensure harmonization of the research protocols for
the studies performed in the different work packages of
the KuBiCo, all active partners have approved final pro-
tocols. This will lead to standardized collection, handling
and storage procedures of the biological samples by the
research groups. This also applies to the questionnaires
on intake of food and supplements, somatic and mental
health, ethics and all developmental follow-ups. In order
Fig. 1 Data collections and timeline of KuBiCo
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to facilitate planned future multinational collaborative
research, all questionnaires are being translated into
English from the original Finnish versions. By standard-
izing all the protocols and questionnaires, optimally
robust and sufficiently powered statistical analyses will
be achieved. Power calculations for the KuBiCo are con-
ducted separately within each individual work package
or research hypothesis using KuBiCo data. In addition,
any missing data is handled separately in each KuBiCo
work package. During study and after completion of the
material collection the KuBiCo database can be linked to
national health registries for epidemiological follow-ups.
Research ethics
The Research Ethics Committee of Hospital District of
Central Finland in Jyväskylä, Finland has reviewed and
approved the KuBiCo plan 15.11.2011. The ethical basis
of KuBiCo is the expected major benefit for future re-
search projects on developmental origin of various child-
hood and adult-onset diseases and the health of future
generations. Data sharing among the participating re-
search groups will make it possible to undertake large
projects, and furthermore, all of the developed data will
remain in the database for future generations of scien-
tists. Pregnant women are asked to consider volunteer
participation, which will involve that they provide their
data and samples. In return, they are automatically
informed about their nutritional or mental health status
if any causes of concern are identified.
Work packages within KuBiCo
Metabolism and omics will study how different risk fac-
tors affect placental hormone production (i.e., potential
for endocrine disruption) and xenobiotics metabolizing
characteristics at different stages of pregnancy by the
means of metabolic activity determination, genetics and
epigenetics.
Paediatrics will survey the somatic health, growth and
overall development of the children by annual question-
naires to elucidate the role of prenatal factors, for ex-
ample maternal smoking and microbe exposure during
birth, on health and morbidity of the offspring in later
childhood, adolescence and adulthood.
Mental wellbeing targets associations between maternal
psychological wellbeing and systemic biomarkers during
pregnancy, and how the maternal mental wellbeing
Fig. 2 Outline of the KuBiCo. Questionnaire and information platform (WebKuBiCo), electronic KuBiCo database (eKuTKa), University of Eastern
Finland (UEF)
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modulates neonate physiology and the child’s later devel-
opment. Furthermore, the psychological development and
wellbeing of the child as well as parent-child relationships
will be studied.
Prenatal period and delivery evaluate perinatal and
genetic epidemiology, and risk factors and markers for
most common obstetrical and perinatal complications,
and how these factors affect the perinatal outcomes and
later the child’s subsequent health. Data is collected on
different prenatal exposures by biological samples and
questionnaires and linked to the information available
on prenatal outcomes and the child’s subsequent health.
Analgesics and anaesthetics during peripartum period
evaluates the foetal and newborn effects of analgesics
and anaesthetics given for parturient during the peri-
natal period. Maternal pharmacokinetics and –dynamics
of different compounds used for pain relief and anaes-
thesia will be measured aimed at establishing a pharma-
codynamic and -kinetic in silico model based on foetal
and newborn exposures evaluated from venous blood.
Environment The studies on the effects of different en-
vironmental exposures are focused on environmental de-
terminants of asthma and allergic diseases, especially of
the exposure to the microbes in indoor air and air pollu-
tion, and of the environmental chemical exposure on the
health and development of the offspring. Environmental
exposures are assessed in KuBiCo with two separate
comprehensive questionnaires during first and third tri-
mesters. In addition, voluntary house dust samples are
collected during first and third trimesters and neonatal
mouth mucosa swab at birth. Also, maternal serum sam-
ples are collected for chemical analyses during first tri-
mester and at birth, and umbilical cord blood samples at
birth if clinically feasible (see Table 1).
Nutrition Intake of food and supplements are collected
using food frequency questionnaire (FFQ) during the
first and third trimester of pregnancy and dietary data of
the children at 2 and 4 years of age. Web-based FFQ
comprises a food list of about 160 food items with nine
frequency response options from “never” to “six or more
times per day”. More than 60 nutrients and 100 food
groups are provided. FFQ includes also specific ques-
tions about supplement use. KuBiCo FFQ has been fur-
ther developed to produce personal feedback about
nutrition at first and third trimester of pregnancy.
Research ethics KuBiCo provides a unique opportunity
to pursue the following important points: 1) recruitment
and informed consent in a birth cohort, 2) evaluation by
the recruited families of the usefulness and potential risks
to their families, 3) handling and long-term storage of
samples and information for future use, 4) societal benefits
of the type of information collected in KuBiCo and 5)
what affects the decisions of the people approached for
recruitment. One of the main aims is to develop reliable
tools to evaluate ethical issues in birth cohort studies.
Descriptive analysis of the KuBiCo database
All material collected between June 2012 and April
2016, altogether 3532 maternal answers to the question-
naires were included in the descriptive analysis.
Additionally, an analysis of demographic data of
mother-child pairs was carried out. This included full
background information and medical records containing
1172 pregnancies, which included 1156 single pregnancies
and 16 twin pregnancies. The background information
collected from the mothers included age, number of medi-
cations, diseases, smoking status, and use of alcohol dur-
ing pregnancy. Information about pregnancies included
the duration of the pregnancy and the weight of placenta.
The newborn information included birthweight, gender
and date of birth. The overall participation in KuBiCo
during 2012–2016 (3532 women) has been 37.3% of all
parturients giving birth in KUH. Table 1 describes the
number of women who filled KuBiCo forms completely
Table 1 Number of participants answering KuBiCo questionnaires from June 2012 to April 2016
General data Total number of participants (per cent of total number of parturients
at Kuopio University Hospital)
3532 (37.3%)
Number of children included in the follow-up study 3187
Women participating in KuBiCo for the second time 230
Number of women answering questionnaires of Ethics 2635
Environmental stress factors – first trimester/last trimester 2464/2134
Nutrition up to gestation week 13/from gestation week 28 to delivery 1625/3240
Mental health 2658
When the child was 12 months old 1955
When the child was 24 months old 1477
Nutrition when the child was 24 months old 1402
When the child was 36 months old 480
Number of women collecting samples Women who completed the collection of house dust 630
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or partly and Table 2 the descriptive characteristics of
the cohort.
Approximately one-fifth of the women had taken at
least one regular medication during pregnancy (Table 3).
Regular medications were mainly related to the women’s
chronic diseases; thyroid diseases, asthma and mental
health conditions which were the most frequent chronic
diseases in pregnant women as expected (Table 4).





n = 81 (6.9)
Term birth
37–40 GWS
n = 855 (73.0)
Late-term birth
≥41 GWS
n = 236 (20.1)
Birth weight, g 3446 ± 597 2156 ± 704 3497 ± 470 3701 ± 395
1st tertile ≤3280 79 (20) 218 (56) 94 (24)
2nd tertile 3281-3700 2 (0.5) 166 (43) 223 (57)
3rd tertile ≥3701 0 (0) 131 (34) 259 (66)
Placental weighta, g 590 ± 130 439 ± 117 592 ± 125 620 ± 124
1st tertile ≤530 51 (13) 179 (47) 155 (40)
2nd tertile 531–630 8 (2.1) 179 (47) 196 (51)
3rd tertile ≥631 2 (0.5) 145 (39) 225 (61)
Maternal ageb, years 29.8 ± 5.1 30.7 ± 5.4 29.9 ± 5.0 29.4 ± 5.3
1st tertile ≤28 21 (4.6) 203 (44) 233 (51)
2nd tertile 29–32 28 (7.4) 161 (43) 188 (50)
3rd tertile ≥33 22 (6.8) 145 (45) 155 (48)
Number of previous deliveriesb 1.0 ± 1.3 0.7 ± 1.1 1.1 ± 1.3 0.7 ± 1.1
Nulliparous 45 (8.8) 210 (41) 258 (50)
Primiparous 14 (3.9) 159 (44) 186 (52)
Multiparous 12 (4.2) 140 (49) 132 (47)
Number of twin pregnancies 16 (1.4) 10 (63) 6 (38) 0 (0)
Gestational week at delivery, weeksb 39.2 ± 2.0 33.5 ± 3.2 39.1 ± 0.9 41.1 ± 0.3
Foetal sex, males 589 (50.3) 42 (51.9) 443 (51.8) 104 (44.1)
Self-reported smoking before pregnancy 226 (20)
Number of daily cigarettes before pregnancyb
No smoking 957 (80) 60 (6.3) 715 (75) 182 (19)
1–10 135 (11.7) 4 (3.0) 93 (69) 38 (28)
≥ 11 64 (5.5) 7 (11) 41 (64) 16 (25)
Self-reported smoking during pregnancy 49 (4.2)
Number of daily cigarettes during pregnancyb
No smoking 1104 (96) 68 (6.2) 811 (74) 225 (20)
1–5 28 (2.4) 1 (3.6) 22 (79) 5 (18)
≥ 6 24 (2.1) 2 (8.3) 16 (67) 6 (25)
Self-reported alcohol consumption before pregnancyb, weekly doses (average)
None 601 (52) 27 (4.5) 468 (78) 106 (18)
1–5 497 (43) 40 (8.0) 343 (69) 114 (23)
≥ 6 58 (5.0) 4 (6.9) 38 (66) 16 (28)
Self-reported alcohol consumption during pregnancyb, monthly (average)
Never 1053 (96) 66 (6.3) 172 (73) 215 (20)
Less than once 36 (3.3) 12 (2.8) 23 (64) 12 (33)
Once a month, and more 11 (1.0) 1 (9.1) 9 (82) 1 (9.1)
Values are n (%) or mean ± SD
aExcluded twin pregnancies, n = 16
bmothers with twin pregnancies included only once, total n = 1156 gestational weeks (GWS)
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Discussion
The organization of the KuBiCo is unique by enabling
linkage of birth cohort biobank with clinical follow-up
and thus creating the possibility to tackle various ques-
tions within the developmental origin of disease concept.
One of the advantages of the KuBiCo is that the
Finnish primary health care system routinely monitors
the pregnant women and children and records their
medical history. The other advantage of KuBiCo is that
all of the questionnaires are in an electronic format, and
can be filled in whenever convenient for the participant.
Every pregnant woman will receive her personal Web-
KuBiCo password that allows her to fill in the form and
to follow the progress of the project. Additionally, some
of the questionnaires (mental health and nutrition) in-
clude automatic feedback to the participant about their
present health status highlighting “safety phrases” if cer-
tain threshold scores are exceeded. These thresholds are
based on established clinical cut-offs [21] and nutritional
guidelines [17]. The aim of this feedback was to motivate
and provide an additional health benefit for the partici-
pating pregnant women, and they have reported that the
feedback has been helpful. Therefore, the developed
feedback service is already included into the daily
routines in the clinics.
To identify selection bias, a descriptive analysis was
performed for 1172 participants of KuBiCo. We found
out that KuBiCo corresponds well with the general
pattern of Finnish pregnancies and deliveries. In the
descriptive analysis (2012–2014), 6.9% of the deliveries
were preterm (< 37 weeks), 73% full-term (37–40 weeks)
and 20.1% late-term (≥41 weeks). In 2015, the corre-
sponding nationwide Finnish delivery statistics were
5.9% preterm, 71.4% full-term and 22.5% late-term deliv-
eries [16]. Mean maternal age in KuBiCo was 29.8 ±
5.1 years and the Finnish average 30.6 years in 2015.
The Finnish mean maternal age has increased by
1.5 years from the 1990s, including older primiparas and
increased numbers of over 35-year old women [16].
The mean birth weight in this descriptive analysis was
3446 ± 597 g (n = 1172) which is similar to the Finnish
mean birthweight i.e. 3485 g in 2015 [16]. Compared to
other Scandinavian countries, the decrease of mean
birthweight has been more significant in Finland since
the 1990s. This decrease of mean birthweight is espe-
cially apparent in boys and in macrosomic foetuses. The
reason for this phenomenon is unknown and a potential
subject for further investigations within and between
cohorts.
There were 16 twin pregnancies in this descriptive
analysis (1.4% of 1156 deliveries) which is equivalent to
the Finnish overall rate of multiple births (13.6/1000
deliveries in 2014) [22]. The twinning rate in Finland is
low when compared to European median twinning rate,
Table 3 Regular use of medication among 1156 women during pregnancy in relation to gestational age at delivery




n = 71 (6.1)
Term birth
37–40 GWS
n = 849 (73.4)
Late-term birth
≥41 GWS
n = 236 (20.4)
No regular medication 928 (80) 52 (6) 683 (74) 193 (21)
Regular medication 228 (20) 19 (8) 166 (73) 43 (19)
1 medication 124 (11) 9 (7) 89 (72) 26 (21)
2 medications 60 (5) 6 (10) 89 (72) 26 (18)
≥ 3 medications 44 (4) 4 (9) 34 (77) 6 (14)
Values are n (%) of all parturients. Gestational weeks (GWS)
Table 4 Women with specific chronic diseases with regular prescription medications initiated before pregnancy in relation to the





n = 71 (6.1)
Term birth
37–40 GWS
n = 849 (73.4)
Late-term birth
≥41 GWS
n = 236 (20.4)
No regular medication 928 (80) 52 (6) 683 (74) 193 (21)
Thyroid diseases 96 (8) 7 (7) 71 (74) 18 (19)
Asthma 60 (5) 6 (10) 43 (72) 11 (18)
Mental health conditions 45 (4) 4 (9) 32 (71) 9 (20)
Neurological diseases 7 (0.6) 1 (14) 2 (29) 4 (58)
Diabetes 10 (0.9) 3 (30) 7 (70) 0
Inflammatory bowel diseases 13 (1) 0 10 (77) 3 (23)
Hypertension 13 (1) 5 (39) 8 (62) 0
Values are n (%) of all parturients. Gestational weeks (GWS)
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which was 16.8% in 2010 [23]. Twin pregnancies carry
higher risks of adverse foetal and neonatal outcomes
such as higher rates of preterm birth, perinatal mortality
and in the longer-term neuro-developmental impair-
ments [23]. In this analysis, ten out of the sixteen twins
(62.5%) were preterm. One reason for the lower rate of
twin pregnancies in Finland may be due to the recom-
mendations of one-embryo transfers in infertility treat-
ment programs.
The gender percentages of the newborns in KuBiCo
were 49.7% girls and 50.3% boys (n = 1172). Based on
the official statistics in Finland, there have been more
boys than girls since 1761 at least until 2015. In the past
twenty years, the proportion of boys has varied between
50.9–51.4% in Finland. In 2015, a total of 55,759
children were born in Finland, and there were 1.3%
more boys than girls [16]. However, sex ratio changes
have been reported from Spain [24], Scotland [25] and
USA [26]. In this descriptive analysis, in the group of
late-term births, the percentage of boys (44.1%) was
lower compared to girls. This signal will need to be
confirmed in the future analyses.
During 1996–2010 in Finland, it was reported that
nearly every second pregnant woman (46.9%) purchased
at least one prescription medication during any trimester
of her pregnancy [14]. In our questionnaire-based data,
20% of women had used at least one regular prescription
medication during pregnancy. It has been shown that
some medications, such as anti-epileptics and antide-
pressants, may increase the risk for preterm birth and
lower birthweight [27]. Lahesmaa-Korpinen and col-
leagues [14] observed that perinatal risks were more fre-
quent when pregnant women are exposed to any
pharmaceuticals during pregnancy. In the same study,
the pregnant women who used medications had a 13%
higher risk to have a small for gestational age newborn,
a 27% higher risk to have a large for gestational age
newborn and a 20% higher risk for preterm delivery in
comparison with those women with no medications. In
accordance with this proposal, we noted that preterm
delivery was more frequent among the women with
regular medication. However, it should be also stated
that most of the women with regular medication deliv-
ered at term or post-term.
Cigarette smoking and use of alcohol are obviously the
most frequent underestimated, but well recognized, con-
founding health factors. Fortunately, smoking during
pregnancy in Finland is decreasing. In 2012, 17% of
pregnant women smoked during pregnancy, but the
percentage is decreasing [22]. In KuBiCo, only about 4%
of the pregnant women reported smoking during preg-
nancy. However, when their smoking status was checked
by serum cotinine determination in a subset, 8.5% had
cotinine in amounts indicating smoking that is
comparable to the levels reported previously [22]. Obvi-
ously, the present numbers are affected by the selection
bias created by e.g. motivation and nicotine replacement
therapy. In KuBiCo placental xenobiotic and steroid
metabolizing enzymatic analysis in vitro [6, 7], confirms
the induction of cytochrome P450 1A1 (CYP1A1) by
smoking.
Based on the comparison of demographic data
between official national statistics and our descriptive
analysis, KuBiCo cohort represents a cross-section of
Finnish pregnant women. KuBiCo is a multidisciplinary
collaborative effort that enables to unravel the effects of
genetics, epigenetics and complex life style factors on
the future health status of both mother and child. The
KuBiCo is equipped with a digital database (eKuTKa) to
serve all contributors; pregnant women can sign in, they
can follow the progress and receive feedback from their
questionnaires; it also permits the registered investiga-
tors’ access the generated data. In its final form, the
database will include the data from 10,000 mother-child
pairs. Our descriptive analysis demonstrates that the
material and the proposed confirmatory measures, for
example smoking status verification, will guarantee the
reliability and high quality of this cohort so that it can
be exploited in future projects and analyses.
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